Related Experiment Video

Updated: Dec 22, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K

Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung

Susan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda

    Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
    |May 3, 2020
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
    11:15

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

    Published on: September 20, 2016

    24.8K
    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
    13:34

    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

    Published on: April 6, 2016

    10.5K

    Related Experiment Videos

    Last Updated: Dec 22, 2025

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
    09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    9.1K
    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
    11:15

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

    Published on: September 20, 2016

    24.8K
    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
    13:34

    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

    Published on: April 6, 2016

    10.5K

    Related Concept Videos

    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    7.6K
    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    7.6K

    Articles linked to this work by shared authors, journal, and citation graph.

    Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum.

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026

    Lung cancer with EGFR PACC mutations: a practical review of available treatment options and novel therapies on the horizon.

    Translational lung cancer research·2026

    Artificial Intelligence Among US Hematology Oncology Fellows: A Multicenter Survey of Education, Attitudes, and Clinical Use.

    JCO oncology practice·2026

    A genetic risk score based on BCL11A and HBS1L-MYB variants predicts clinical severity in Brazilian sickle cell anaemia patients.

    British journal of haematology·2026

    ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia.

    Cell reports. Medicine·2026

    Vitamin D receptor gene polymorphisms and 25-hydroxyvitamin D levels: association with cerebrovascular disease in sickle cell anemia.

    Pediatric hematology and oncology·2025

    Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Topoisomerase-Based CDH17 Antibody Drug Conjugates Overcome P-gp Resistance but Undergo Target Mediated Clearance in Colorectal Cancer.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Progress in Clinical Care and Research for Li-Fraumeni Syndrome: Perspectives from the 7th Li-Fraumeni Syndrome Association REACH Symposium.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Endotrophin is a circulating fibroinflammatory biomarker associated with treatment response in human metastatic ER+ breast cancer.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lung Cancers: A Phase II Trial of Cabozantinib.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Long-term outcomes of modified-intensity lenalidomide, bortezomib and dexamethasone (RVD-lite) in transplant-ineligible multiple myeloma: final report of a phase II trial.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Chlorogenic Acid Derivative B11 Inhibits Glioma Proliferation by Targeting MST4 to Regulate Oxidative Stress.

    Molecular carcinogenesis·2026

    CNOT4 Suppresses Bladder Cancer Progression by Promoting Ubiquitination-Mediated Degradation of EIF2AK2 and Inhibiting Autophagy.

    Molecular carcinogenesis·2026

    Global Disparities in the Availability and Reimbursement of Systemic Therapies for Renal Cell Carcinoma: Results of the International ARON-AID Survey.

    The oncologist·2026

    Targeting RAS in pancreatic cancer.

    Cancer·2026

    Late effects after novel therapies for childhood cancer: Anticipating the future landscape of health outcomes for survivors.

    Journal of the National Cancer Institute·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us